Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Saruparib · AZD-5305

Small molecule · Inhibitor of poly(ADP-ribose) polymerase (PARP) (PARP1) · developed by ASTRAZENECA

Phase 3 Most advanced trial
AZN Developer
2 Registered trials

What is Saruparib?

Saruparib is an orally bioavailable inhibitor of poly(ADP-ribose) polymerase (PARP). It binds PARP and blocks PARP-mediated repair of single-strand DNA breaks through base-excision repair, leading to DNA strand break accumulation and apoptosis. It is being studied in pancreatic ductal adenocarcinoma, metastatic castration-sensitive prostate cancer, and solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AZD-5305, 2589531-76-8
Drug type
Small molecule
Targets
poly(ADP-ribose) polymerase (PARP) (PARP1)
Mechanism
Inhibitor of poly(ADP-ribose) polymerase (PARP) (PARP1)
Pathways
base-excision repair, DNA strand break repair, apoptosis
Therapy area
Oncology
Developer
ASTRAZENECA (AZN)
Also in trials of
CRDF
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
16MZ1V3RBT

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06713369 Phase 1 Locally Advanced or Metastatic Solid Tumor Recruiting AZN
NCT04005690 Early Phase 1 Locally Advanced Pancreatic Ductal Adenocarcinoma Recruiting CRDF

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Borderline Resectable Pancreatic Ductal AdenocarcinomaLocally Advanced or Metastatic Solid TumorLocally Advanced Pancreatic Ductal AdenocarcinomaMetastatic Castration-Sensitive Prostate CancerMetastatic Pancreatic Ductal AdenocarcinomaResectable Pancreatic Ductal AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Pancreatic Ductal Adenocarcinoma

Other drugs acting on PARP1

More from ASTRAZENECA

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the AZN page.

Follow AZN, the company behind Saruparib

See AZN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AZN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.